Terms: = Germ cell tumor AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Clinical Outcome
10 results:
1. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
2. Dendritic cells cross-talk with tumour antigen-specific CD8
Eiraku Y; Terunuma H; Yagi M; Deng X; Nicol AJ; Nieda M
Clin Exp Immunol; 2018 Oct; 194(1):54-66. PubMed ID: 30009488
[TBL] [Abstract] [Full Text] [Related]
3. tumor-Infiltrating Merkel cell Polyomavirus-Specific T cells Are Diverse and Associated with Improved Patient Survival.
Miller NJ; Church CD; Dong L; Crispin D; Fitzgibbon MP; Lachance K; Jing L; Shinohara M; Gavvovidis I; Willimsky G; McIntosh M; Blankenstein T; Koelle DM; Nghiem P
Cancer Immunol Res; 2017 Feb; 5(2):137-147. PubMed ID: 28093446
[TBL] [Abstract] [Full Text] [Related]
4. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract] [Full Text] [Related]
5. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial.
Ribas A; Weber JS; Chmielowski B; Comin-Anduix B; Lu D; Douek M; Ragavendra N; Raman S; Seja E; Rosario D; Miles S; Diamond DC; Qiu Z; Obrocea M; Bot A
Clin Cancer Res; 2011 May; 17(9):2987-96. PubMed ID: 21385924
[TBL] [Abstract] [Full Text] [Related]
6. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
Ginsberg BA; Gallardo HF; Rasalan TS; Adamow M; Mu Z; Tandon S; Bewkes BB; Roman RA; Chapman PB; Schwartz GK; Carvajal RD; Panageas KS; Terzulli SL; Houghton AN; Yuan JD; Wolchok JD
Clin Cancer Res; 2010 Aug; 16(15):4057-65. PubMed ID: 20647477
[TBL] [Abstract] [Full Text] [Related]
7. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
Butterfield LH; Ribas A; Dissette VB; Amarnani SN; Vu HT; Oseguera D; Wang HJ; Elashoff RM; McBride WH; Mukherji B; Cochran AJ; Glaspy JA; Economou JS
Clin Cancer Res; 2003 Mar; 9(3):998-1008. PubMed ID: 12631598
[TBL] [Abstract] [Full Text] [Related]
8. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract] [Full Text] [Related]
9. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract] [Full Text] [Related]
10. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
[TBL] [Abstract] [Full Text] [Related]
